

# Pengcheng Shi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5089264/publications.pdf>

Version: 2024-02-01

53  
papers

636  
citations

933447

10  
h-index

610901

24  
g-index

53  
all docs

53  
docs citations

53  
times ranked

877  
citing authors

#	ARTICLE	IF	CITATIONS
1	Cidofovir, a choice for salvage treatment of cytomegalovirus infection in patients with haploidentical hematopoietic stem cell transplantation. <i>Transplant Infectious Disease</i> , 2022, 24, .	1.7	2
2	A phase 2 study of sorafenib combined with conventional therapies in refractory central nervous system leukemia. <i>Cancer</i> , 2022, , .	4.1	5
3	Low-Dose Triptolide Enhanced Activity of Idarubicin Against Acute Myeloid Leukemia Stem-like Cells Via Inhibiting DNA Damage Repair Response. <i>Stem Cell Reviews and Reports</i> , 2021, 17, 616-627.	3.8	4
4	IL-6 trans-signaling promotes the expansion and anti-tumor activity of CAR T cells. <i>Leukemia</i> , 2021, 35, 1380-1391.	7.2	26
5	Comparison of Two Strategies for Prophylactic Donor Lymphocyte Infusion in Patients With Refractory/Relapsed Acute Leukemia. <i>Frontiers in Oncology</i> , 2021, 11, 554503.	2.8	8
6	Metagenomic next-generation sequencing for identifying pathogens in central nervous system complications after allogeneic hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 1978-1983.	2.4	14
7	Upfront transplantation may have better outcomes than pretransplant cytoreductive therapy for treating patients with <scp>MDS&€B</scp>â€1 or <scp>MDS&€B</scp>â€2. <i>International Journal of Cancer</i> , 2021, 149, 1109-1120.	5.1	6
8	Disulfiram/copper shows potent cytotoxic effects on myelodysplastic syndromes via inducing Bip-mediated apoptosis and suppressing autophagy. <i>European Journal of Pharmacology</i> , 2021, 902, 174107.	3.5	5
9	Association Between Measurable Residual Disease in Patients With Intermediate-Risk Acute Myeloid Leukemia and First Remission, Treatment, and Outcomes. <i>JAMA Network Open</i> , 2021, 4, e2115991.	5.9	12
10	The Impact of CD19 Expression Combined with Measurable Residual Disease on Post-Remission Treatment and Outcome in Adult t(8;21) Acute Myeloid Leukemia. <i>Blood</i> , 2021, 138, 4445-4445.	1.4	0
11	Haploidentical transplantation has a superior graft-versus-leukemia effect than HLA-matched sibling transplantation for Phâ~ high-risk B-cell acute lymphoblastic leukemia. <i>Chinese Medical Journal</i> , 2021, Publish Ahead of Print, .	2.3	4
12	Retrospective Analysis of Bronchiolitis Obliterans Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2021, 138, 4877-4877.	1.4	2
13	Dynamic assessment of measurable residual disease in favorable-risk acute myeloid leukemia in first remission, treatment, and outcomes. <i>Blood Cancer Journal</i> , 2021, 11, 195.	6.2	8
14	Disruption of CTCF Boundary at HOXA Locus Promote BET Inhibitorsâ€™ Therapeutic Sensitivity in Acute Myeloid Leukemia. <i>Stem Cell Reviews and Reports</i> , 2020, 16, 1280-1291.	3.8	3
15	Haploidentical related donor vs matched sibling donor allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia and myelodysplastic syndrome aged over 50 years: A singleâ€center retrospective study. <i>Cancer Medicine</i> , 2020, 9, 6244-6255.	2.8	9
16	Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 1201-1212.	10.7	209
17	Graft-vs-Host Diseaseâ€Induced Hyperthyroidism in a Recipient of Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report. <i>Transplantation Proceedings</i> , 2020, 52, 2854-2857.	0.6	2
18	Cidofovir, a Choice for Salvage Treatment of CMV Infection in the Patients with Haploidentical Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2020, 136, 40-41.	1.4	1

#	ARTICLE	IF	CITATIONS
19	Combination of Homoharringtonine with Venetoclax and Azacitidine Exerts Better Treatment Response in Relapsed /Refractory Acute Myeloid Leukemia. <i>Blood</i> , 2020, 136, 26-27.	1.4	4
20	Apatinib exerts anti-tumor activity to non-Hodgkin lymphoma by inhibition of the Ras pathway. <i>European Journal of Pharmacology</i> , 2019, 843, 145-153.	3.5	11
21	A retrospective comparison of Escherichia $\hat{A}$ $\hat{A}$ $\hat{A}$ 1/2coli and polyethylene glycolâ€™conjugated asparaginase for the treatment of adolescents and adults with newly diagnosed acute lymphoblastic leukemia. <i>Oncology Letters</i> , 2018, 15, 75-82.	1.8	10
22	Efficacy and Safety of Ruxolitinib in Treatment of Steroid Refractory/Refractory Acute Graft-Versus-Host Disease: A Prospective Multicenter Research. <i>Blood</i> , 2018, 132, 5724-5724.	1.4	0
23	Allogeneic hematopoietic stem cell transplantation improves the prognosis of <i>p16</i> -deleted adult patients with acute lymphoblastic leukemia. <i>Pharmacogenomics</i> , 2017, 18, 77-84.	1.3	7
24	The pan-Bcl2 Inhibitor AT101 Activates the Intrinsic Apoptotic Pathway and Causes DNA Damage in Acute Myeloid Leukemia Stem-Like Cells. <i>Targeted Oncology</i> , 2017, 12, 677-687.	3.6	13
25	Low-dose decitabine enhances chidamide-induced apoptosis in adult acute lymphoblast leukemia, especially for <i>p16</i> -deleted patients through DNA damage. <i>Pharmacogenomics</i> , 2017, 18, 1259-1270.	1.3	17
26	CXCR5+CD8+ T cells present elevated capacity in mediating cytotoxicity toward autologous tumor cells through interleukin 10 in diffuse large B-cell lymphoma. <i>International Immunopharmacology</i> , 2017, 50, 146-151.	3.8	21
27	Low dose triptolide reverses chemoresistance in adult acute lymphoblastic leukemia cells via reactive oxygen species generation and DNA damage response disruption. <i>Oncotarget</i> , 2016, 7, 85515-85528.	1.8	21
28	Tigecycline Was a Promising Candidate for Febrile Neutropenic and Carbapenem-Resistant Patients with Hematologic Malignancy. <i>Blood</i> , 2015, 126, 4610-4610.	1.4	0
29	Low MDR1 and BAALC expression identifies a new subgroup of intermediate cytogenetic risk acute myeloid leukemia with a favorable outcome. <i>Blood Cells, Molecules, and Diseases</i> , 2014, 53, 144-148.	1.4	13
30	Prophylactic Use of Sorafenib in Patients with FLT3-ITD-Positive Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2014, 124, 3943-3943.	1.4	2
31	Utility of F-18 FDG PET/CT for the Diagnosis and Therapeutic Management of Extranodal Natural Killer (NK)/T-Cell Lymphoma, Nasal Type. <i>Blood</i> , 2014, 124, 1704-1704.	1.4	0
32	Triptolide, a Chinese herbal extract, enhances drug sensitivity of resistant myeloid leukemia cell lines through downregulation of HIF-1 $\alpha$ and Nrf2. <i>Pharmacogenomics</i> , 2013, 14, 1305-1317.	1.3	35
33	Idarubicin is superior to daunorubicin in remission induction of <i>de novo</i> acute myeloid leukemia patients with high <i>MDR1</i> expression. <i>Pharmacogenomics</i> , 2013, 14, 17-23.	1.3	8
34	Disulfiram, an Clinically Used Anti-Alcoholism Drug Has the Potential to Target Leukemia Stem and Progenitor Cells in a Copper-Dependent Manner. <i>Blood</i> , 2012, 120, 4088-4088.	1.4	0
35	Comparative Efficacy of Homoharringtonine Plus Cytarabine and Decitabine in Patients with MDS/AML. <i>Blood</i> , 2012, 120, 4340-4340.	1.4	0
36	Activation of Oxidative Stress and Down-Regulation of Nuclear Factor Erythroid 2-Related Factor May Be Responsible for Disulfiram/Copper Complex Induced Apoptosis in Lymphoid Malignancy Cell Lines. <i>Blood</i> , 2012, 120, 4869-4869.	1.4	10

#	ARTICLE	IF	CITATIONS
37	Low MDR1 and BAALC expression Identifies a New Subgroup of Adult Cytogenetically Normal Acute Myeloid Leukemia with a Favorable Outcome. <i>Blood</i> , 2012, 120, 4312-4312.	1.4	0
38	Nonlocal Prior Bayesian Tomographic Reconstruction. <i>Journal of Mathematical Imaging and Vision</i> , 2008, 30, 133-146.	1.3	126
39	ROBUST RECONSTRUCTION OF PHYSIOLOGICAL PARAMETERS FROM DYNAMIC PET DATA. , 2007, , .		0
40	Constrained Nonlinear Estimation of fMRI Hemodynamic Response Parameters. , 2007, , .		0
41	Joint Estimation for Nonlinear Dynamic System from fMRI Time Series. , 2007, , .		1
42	SIMULTANEOUS RECOVERY OF LEFT VENTRICULAR MOTION AND INPUT FORCES FROM MEDICAL IMAGE SEQUENCES. , 2007, , .		3
43	A Novel Method of Correcting the Sinogram Data for Positron Emission Tomography. , 2007, , .		0
44	NONINVASIVE IMAGING OF 3D CARDIAC ELECTROPHYSIOLOGY. , 2007, , .		3
45	Bayesian Reconstruction Using A Novel Nonlocal MRF Prior for PET Transmission Tomography. , 2007, , .		0
46	VOLUMETRIC MESHFREE FRAMEWORK FOR JOINT SEGMENTATION AND MOTION TRACKING OF THE LEFT VENTRICLE. , 2007, , .		2
47	Performance Results of BGO Block Detectors Based on Flat Panel PS-PMT for PET. <i>IEEE Transactions on Nuclear Science</i> , 2007, 54, 1298-1301.	2.0	2
48	A Novel Nonlocal QuadraticMRF Prior Model for Positron Emission Tomography. , 2007, , .		0
49	Sampled-Data $\hat{I} \pm$ Filtering for Robust Kinematics Estimation: Applications to Biomechanics-Based Cardiac Image Analysis. , 2006, , .		1
50	Regularity and Complexity of Human Electroencephalogram Dynamics: Applications to Diagnosis of Alzheimers Disease. , 2006, , .		4
51	Stochastic Framework for Symmetric Affine Matching between Point Sets. , 2006, , .		0
52	Normalization of Functional Magnetic Resonance Images by Classified Cerebrospinal Fluid Cluster. , 2006, , .		2
53	State-Space Reconstruction of Pet Parametric Maps. , 2006, , .		0